Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tau knockin mice

Neurobiology of Aging

Volumn 39, Issue , 2016, Pages 1-18

  Gilley, Jonathan ^a   Ando, Kunie ^b   Seereeram, Anjan ^c   Rodríguez Martín, Teresa ^c   Pooler, Amy M ^c   Sturdee, Laura ^a   Anderton, Brian H ^c   Brion, Jean Pierre ^b   Hanger, Diane P ^c   Coleman, Michael P ^a,d  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Hyperphosphorylation; Knockin mouse; Phosphodefective; Phosphomimetic; Tau; Tauopathy

Indexed keywords

ALANINE; BETA TUBULIN; BETAIII TUBULIN; GLUTAMIC ACID; SERINE; SYNAPTOPHYSIN; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG; MAPT PROTEIN, HUMAN; MAPT PROTEIN, MOUSE;

ADULT; AGE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CELL TRANSPORT; CELLULAR DISTRIBUTION; CEREBELLUM; CONTROLLED STUDY; DENTATE HILUS; FEMALE; GENE; HIPPOCAMPAL CA3 REGION; MAPT GENE; MEMBRANE BINDING; MICROTUBULE; MITOCHONDRION; MOUSE; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MISLOCALIZATION; PROTEIN PHOSPHORYLATION; TIBIAL NERVE; ANIMAL; GENETICS; HUMAN; METABOLISM; MUTANT MOUSE STRAIN; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; PROTEINOSIS; TAUOPATHY;

ANIMALS; HUMANS; MICE, MUTANT STRAINS; NEURONS; PHOSPHORYLATION; PROTEIN AGGREGATION, PATHOLOGICAL; TAU PROTEINS; TAUOPATHIES;

EID: 84959462799     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.11.028     Document Type: Article

References (84)

1. Adams S.J., Crook R.J., Deture M., Randle S.J., Innes A.E., Yu X.Z., Lin W.L., Dugger B.N., McBride M., Hutton M., Dickson D.W., McGowan E. Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. Am. J. Pathol. 2009, 175:1598-1609.
2. Ahlijanian M.K., Barrezueta N.X., Williams R.D., Jakowski A., Kowsz K.P., McCarthy S., Coskran T., Carlo A., Seymour P.A., Burkhardt J.E., Nelson R.B., McNeish J.D. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2910-2915.
3. Ambegaokar S.S., Jackson G.R. Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum. Mol. Genet. 2011, 20:4947-4977.
4. Ando K., Leroy K., Heraud C., Kabova A., Yilmaz Z., Authelet M., Suain V., De Decker R., Brion J.P. Deletion of murine tau gene increases tau aggregation in a human mutant tau transgenic mouse model. Biochem. Soc. Trans. 2010, 38:1001-1005.
5. Ando K., Leroy K., Heraud C., Yilmaz Z., Authelet M., Suain V., De Decker R., Brion J.P. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am. J. Pathol. 2011, 178:803-816.
6. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K.L., Barde Y.A., Duff K., Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 2003, 86:582-590.
7. Andreadis A., Brown W.M., Kosik K.S. Structure and novel exons of the human tau gene. Biochemistry 1992, 31:10626-10633.
8. Andrews S., Gilley J., Coleman M.P. Difference Tracker: ImageJ plugins for fully automated analysis of multiple axonal transport parameters. J. Neurosci. Methods 2010, 193:281-287.
9. Arrasate M., Perez M., Avila J. Tau dephosphorylation at tau-1 site correlates with its association to cell membrane. Neurochem. Res. 2000, 25:43-50.
10. Baglietto-Vargas D., Kitazawa M., Le E.J., Estrada-Hernandez T., Rodriguez-Ortiz C.J., Medeiros R., Green K.N., LaFerla F.M. Endogenous murine tau promotes neurofibrillary tangles in 3xTg-AD mice without affecting cognition. Neurobiol. Dis. 2014, 62:407-415.
11. Bancher C., Brunner C., Lassmann H., Budka H., Jellinger K., Wiche G., Seitelberger F., Grundke-Iqbal I., Iqbal K., Wisniewski H.M. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res. 1989, 477:90-99.
12. Biernat J., Gustke N., Drewes G., Mandelkow E.M., Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11:153-163.
13. Black M.M., Slaughter T., Moshiach S., Obrocka M., Fischer I. Tau is enriched on dynamic microtubules in the distal region of growing axons. J. Neurosci. 1996, 16:3601-3619.
14. Braak E., Braak H., Mandelkow E.M. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 1994, 87:554-567.
15. Bramblett G.T., Goedert M., Jakes R., Merrick S.E., Trojanowski J.Q., Lee V.M. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993, 10:1089-1099.
16. Bramblett G.T., Trojanowski J.Q., Lee V.M. Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins). Lab. Invest. 1992, 66:212-222.
17. Brandt R., Lee G. Functional organization of microtubule-associated protein tau. Identification of regions which affect microtubule growth, nucleation, and bundle formation in vitro. J. Biol. Chem. 1993, 268:3414-3419.
18. Brandt R., Leger J., Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J. Cell Biol. 1995, 131:1327-1340.
19. Brion J.P., Hanger D.P., Bruce M.T., Couck A.M., Flament-Durand J., Anderton B.H. Tau in Alzheimer neurofibrillary tangles. N- and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. Biochem. J. 1991, 273(Pt 1):127-133.
20. Brion J.P., Smith C., Couck A.M., Gallo J.M., Anderton B.H. Developmental changes in tau phosphorylation: fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of Alzheimer's disease. J. Neurochem. 1993, 61:2071-2080.
21. Busciglio J., Lorenzo A., Yeh J., Yankner B.A. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995, 14:879-888.
22. Chatterjee S., Sang T.K., Lawless G.M., Jackson G.R. Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum. Mol. Genet. 2009, 18:164-177.
23. Chohan M.O., Haque N., Alonso A., El-Akkad E., Grundke-Iqbal I., Grover A., Iqbal K. Hyperphosphorylation-induced self assembly of murine tau: a comparison with human tau. J. Neural Transm. 2005, 112:1035-1047.
24. Cruz J.C., Tseng H.C., Goldman J.A., Shih H., Tsai L.H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40:471-483.
25. Cuchillo-Ibanez I., Seereeram A., Byers H.L., Leung K.Y., Ward M.A., Anderton B.H., Hanger D.P. Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J. 2008, 22:3186-3195.
26. Davis D.R., Brion J.P., Couck A.M., Gallo J.M., Hanger D.P., Ladhani K., Lewis C., Miller C.C., Rupniak T., Smith C., Anderton B.H. The phosphorylation state of the microtubule-associated protein tau as affected by glutamate, colchicine and beta-amyloid in primary rat cortical neuronal cultures. Biochem. J. 1995, 309(Pt 3):941-949.
27. Dawson H.N., Ferreira A., Eyster M.V., Ghoshal N., Binder L.I., Vitek M.P. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 2001, 114(Pt 6):1179-1187.
28. Denk F., Wade-Martins R. Knock-out and transgenic mouse models of tauopathies. Neurobiol. Aging 2009, 30:1-13.
29. Dickey C.A., Kamal A., Lundgren K., Klosak N., Bailey R.M., Dunmore J., Ash P., Shoraka S., Zlatkovic J., Eckman C.B., Patterson C., Dickson D.W., Nahman N.S., Hutton M., Burrows F., Petrucelli L. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 2007, 117:648-658.
30. Ding H., Matthews T.A., Johnson G.V. Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J. Biol. Chem. 2006, 281:19107-19114.
31. Drewes G., Trinczek B., Illenberger S., Biernat J., Schmitt-Ulms G., Meyer H.E., Mandelkow E.M., Mandelkow E. Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J. Biol. Chem. 1995, 270:7679-7688.
32. Eidenmuller J., Fath T., Maas T., Pool M., Sontag E., Brandt R. Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochem. J. 2001, 357(Pt 3):759-767.
33. Fujio K., Sato M., Uemura T., Sato T., Sato-Harada R., Harada A. 14-3-3 proteins and protein phosphatases are not reduced in tau-deficient mice. Neuroreport 2007, 18:1049-1052.
34. Gilley J., Adalbert R., Coleman M.P. Modelling early responses to neurodegenerative mutations in mice. Biochem. Soc. Trans. 2011, 39:933-938.
35. Gilley J., Adalbert R., Yu G., Coleman M.P. Rescue of peripheral and CNS axon defects in mice lacking NMNAT2. J. Neurosci. 2013, 33:13410-13424.
36. Gilley J., Coleman M.P. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol. 2010, 8:e1000300.
37. Gilley J., Seereeram A., Ando K., Mosely S., Andrews S., Kerschensteiner M., Misgeld T., Brion J.P., Anderton B., Hanger D.P., Coleman M.P. Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse. Neurobiol. Aging 2012, 33:621.e1-621.e15.
38. Goode B.L., Denis P.E., Panda D., Radeke M.J., Miller H.P., Wilson L., Feinstein S.C. Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. Mol. Biol. Cell 1997, 8:353-365.
39. Hanger D.P., Anderton B.H., Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 2009, 15:112-119.
40. Hanger D.P., Betts J.C., Loviny T.L., Blackstock W.P., Anderton B.H. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 1998, 71:2465-2476.
41. Hanger D.P., Byers H.L., Wray S., Leung K.Y., Saxton M.J., Seereeram A., Reynolds C.H., Ward M.A., Anderton B.H. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 2007, 282:23645-23654.
42. Harada A., Oguchi K., Okabe S., Kuno J., Terada S., Ohshima T., Sato-Yoshitake R., Takei Y., Noda T., Hirokawa N. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 1994, 369:488-491.
43. Hirokawa N., Funakoshi T., Sato-Harada R., Kanai Y. Selective stabilization of tau in axons and microtubule-associated protein 2C in cell bodies and dendrites contributes to polarized localization of cytoskeletal proteins in mature neurons. J. Cell Biol. 1996, 132:667-679.
44. Hundelt M., Fath T., Selle K., Oesterwind K., Jordan J., Schultz C., Gotz J., von Engelhardt J., Monyer H., Lewejohann L., Sachser N., Bakota L., Brandt R. Altered phosphorylation but no neurodegeneration in a mouse model of tau hyperphosphorylation. Neurobiol. Aging 2011, 32:991-1006.
45. Iqbal K., Gong C.X., Liu F. Hyperphosphorylation-induced tau oligomers. Front. Neurol. 2013, 4:112.
46. Ittner L.M., Gotz J. Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:65-72.
47. Johnson G.V., Stoothoff W.H. Tau phosphorylation in neuronal cell function and dysfunction. J. Cell Sci. 2004, 117(Pt 24):5721-5729.
48. Kampers T., Pangalos M., Geerts H., Wiech H., Mandelkow E. Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease. FEBS Lett. 1999, 451:39-44.
49. Kanai Y., Takemura R., Oshima T., Mori H., Ihara Y., Yanagisawa M., Masaki T., Hirokawa N. Expression of multiple tau isoforms and microtubule bundle formation in fibroblasts transfected with a single tau cDNA. J. Cell Biol. 1989, 109:1173-1184.
50. Kiris E., Ventimiglia D., Sargin M.E., Gaylord M.R., Altinok A., Rose K., Manjunath B.S., Jordan M.A., Wilson L., Feinstein S.C. Combinatorial Tau pseudophosphorylation: markedly different regulatory effects on microtubule assembly and dynamic instability than the sum of the individual parts. J. Biol. Chem. 2011, 286:14257-14270.
51. Kolarova M., Garcia-Sierra F., Bartos A., Ricny J., Ripova D. Structure and pathology of tau protein in Alzheimer disease. Int. J. Alzheimers Dis. 2012, 2012:731526.
52. Kopke E., Tung Y.C., Shaikh S., Alonso A.C., Iqbal K., Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 1993, 268:24374-24384.
53. Ksiezak-Reding H., Liu W.K., Yen S.H. Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res. 1992, 597:209-219.
54. Lasagna-Reeves C.A., Castillo-Carranza D.L., Sengupta U., Sarmiento J., Troncoso J., Jackson G.R., Kayed R. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 2012, 26:1946-1959.
55. Lee G., Newman S.T., Gard D.L., Band H., Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci. 1998, 111(Pt 21):3167-3177.
56. Leger J., Kempf M., Lee G., Brandt R. Conversion of serine to aspartate imitates phosphorylation-induced changes in the structure and function of microtubule-associated protein tau. J. Biol. Chem. 1997, 272:8441-8446.
57. Leroy K., Bretteville A., Schindowski K., Gilissen E., Authelet M., De Decker R., Yilmaz Z., Buee L., Brion J.P. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am. J. Pathol. 2007, 171:976-992.
58. Li X., Kumar Y., Zempel H., Mandelkow E.M., Biernat J., Mandelkow E. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J. 2011, 30:4825-4837.
59. Liou Y.C., Sun A., Ryo A., Zhou X.Z., Yu Z.X., Huang H.K., Uchida T., Bronson R., Bing G., Li X., Hunter T., Lu K.P. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003, 424:556-561.
60. Luo W., Dou F., Rodina A., Chip S., Kim J., Zhao Q., Moulick K., Aguirre J., Wu N., Greengard P., Chiosis G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9511-9516.
61. Maas T., Eidenmuller J., Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J. Biol. Chem. 2000, 275:15733-15740.
62. Mietelska-Porowska A., Wasik U., Goras M., Filipek A., Niewiadomska G. Tau protein modifications and interactions: their role in function and dysfunction. Int. J. Mol. Sci. 2014, 15:4671-4713.
63. Migheli A., Butler M., Brown K., Shelanski M.L. Light and electron microscope localization of the microtubule-associated tau protein in rat brain. J. Neurosci. 1988, 8:1846-1851.
64. Misgeld T., Kerschensteiner M., Bareyre F.M., Burgess R.W., Lichtman J.W. Imaging axonal transport of mitochondria in vivo. Nat. Methods 2007, 4:559-561.
65. Morris M., Knudsen G.M., Maeda S., Trinidad J.C., Ioanoviciu A., Burlingame A.L., Mucke L. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 2015, 18:1183-1189.
66. Noble W., Hanger D.P., Gallo J.M. Transgenic mouse models of tauopathy in drug discovery. CNS Neurol. Disord. Drug Targets 2010, 9:403-428.
67. Noble W., Hanger D.P., Miller C.C., Lovestone S. The importance of tau phosphorylation for neurodegenerative diseases. Front. Neurol. 2013, 4:83.
68. Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., Gaynor K., LaFrancois J., Wang L., Kondo T., Davies P., Burns M., Veeranna, Nixon R., Dickson D., Matsuoka Y., Ahlijanian M., Lau L.F., Duff K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003, 38:555-565.
69. Peng I., Binder L.I., Black M.M. Biochemical and immunological analyses of cytoskeletal domains of neurons. J. Cell Biol. 1986, 102:252-262.
70. Pooler A.M., Usardi A., Evans C.J., Philpott K.L., Noble W., Hanger D.P. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol. Aging 2012, 33:431.e27-431.e38.
71. Poppek D., Keck S., Ermak G., Jung T., Stolzing A., Ullrich O., Davies K.J., Grune T. Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem. J. 2006, 400:511-520.
72. Rankin C.A., Sun Q., Gamblin T.C. Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation. Brain Res. Mol. Brain Res. 2005, 138:84-93.
73. Reynolds C.H., Garwood C.J., Wray S., Price C., Kellie S., Perera T., Zvelebil M., Yang A., Sheppard P.W., Varndell I.M., Hanger D.P., Anderton B.H. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J. Biol. Chem. 2008, 283:18177-18186.
74. Rodriguez-Martin T., Cuchillo-Ibanez I., Noble W., Nyenya F., Anderton B.H., Hanger D.P. Tau phosphorylation affects its axonal transport and degradation. Neurobiol. Aging 2013, 34:2146-2157.
75. Schneider A., Biernat J., von Bergen M., Mandelkow E., Mandelkow E.M. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999, 38:3549-3558.
76. Smith M.J., Crowther R.A., Goedert M. The natural osmolyte trimethylamine N-oxide (TMAO) restores the ability of mutant tau to promote microtubule assembly. FEBS Lett. 2000, 484:265-270.
77. Spittaels K., Van den Haute C., Van Dorpe J., Geerts H., Mercken M., Bruynseels K., Lasrado R., Vandezande K., Laenen I., Boon T., Van Lint J., Vandenheede J., Moechars D., Loos R., Van Leuven F. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 2000, 275:41340-41349.
78. Takuma H., Arawaka S., Mori H. Isoforms changes of tau protein during development in various species. Brain Res. Dev. Brain Res. 2003, 142:121-127.
79. Terwel D., Muyllaert D., Dewachter I., Borghgraef P., Croes S., Devijver H., Van Leuven F. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol. 2008, 172:786-798.
80. Trinczek B., Biernat J., Baumann K., Mandelkow E.M., Mandelkow E. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol. Biol. Cell. 1995, 6:1887-1902.
81. Wagner U., Utton M., Gallo J.M., Miller C.C. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J. Cell Sci. 1996, 109(Pt 6):1537-1543.
82. Wolfe M.S. Tau mutations in neurodegenerative diseases. J. Biol. Chem. 2009, 284:6021-6025.
83. Zempel H., Mandelkow E. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci. 2014, 37:721-732.
84. Zilka N., Kovacech B., Barath P., Kontsekova E., Novak M. The self-perpetuating tau truncation circle. Biochem. Soc. Trans. 2012, 40:681-686.